Novo's acquisition has legal ramifications: Dicerna sued by shareholders

A number of shareholders in US-based Dicerna have sued over an alleged breach of the US Securities Exchange Act, following the announcement of Novo Nordisk's planned acquisition of the US-based biotech firm.

Danish pharmaceutical firm Novo Nordisk could be entagled in a legal dispute in the US, as a number of shareholders in Dicerna have sued the US-based firm following the news of Novo Nordisk's planned acquisition. | Photo: Jacob Ehrbahn/Politiken

Novo Nordisk's acquisition of US-based biotech firm Dicerna for USD 3.3bn has been hit by a legal aftermath. Shareholders in Dicerna have filed separate suits against the firm and its board of directors, alleging violations of the US Securities Exchange Act, reports Law Street Media.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs